Live feed07:00:00·1470dPRReleasevia QuantisnowImmunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022ByQuantisnow·Wall Street's wire, on your screen.IMVT· Immunovant Inc.Health Care
